Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
- Conditions
- Prostate CancerProstate AdenocarcinomaBiochemical Recurrence of Malignant Neoplasm of Prostate
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Curium US LLC
- Target Recruit Count
- 235
- Registration Number
- NCT06235099
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Tower Urology, Los Angeles, California, United States
🇺🇸VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- Conditions
- Prostate AdenocarcinomaProstate Cancer
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Curium US LLC
- Target Recruit Count
- 323
- Registration Number
- NCT06235151
- Locations
- 🇺🇸
VA Boston Healthcare System, Boston, Massachusetts, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Providence Medical Foundation, Fullerton, California, United States
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
- Conditions
- Metastasis From Malignant Tumor of Prostate (Disorder)
- Interventions
- Drug: 64Cu-PSMA I&T
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Curium US LLC
- Target Recruit Count
- 29
- Registration Number
- NCT05653856
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸John J. Cochran Veterans Hospital, Saint Louis, Missouri, United States
🇺🇸Edward Hines, Jr. VA Hospital, Hines, Illinois, United States
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastasis From Malignant Tumor of Prostate
- Interventions
- Drug: Abiraterone with Prednisone or EnzalutamideDrug: 177Lu-PSMA-I&T
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Curium US LLC
- Target Recruit Count
- 439
- Registration Number
- NCT05204927
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇪🇸Hospital Regional Universitario de Malaga, Málaga, Spain
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Curium US LLC
- Registration Number
- NCT04334837